0001314052 false 0001314052 2022-05-24 2022-05-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 24, 2022

 

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada 001-37606 98-0608404
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

630 5th Avenue, 20th Floor, New York, NY USA 10111
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code 1-844-689-3939

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, $0.001 par value   AVXL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 24, 2022, the Company held its Annual Meeting. A total of 53,355,147 shares of the Company’s Common Stock were present or represented by proxy at the Annual Meeting, representing approximately sixty nine percent (69%) of the outstanding Common Stock as of March 28, 2022, the record date for the Annual Meeting.

 

At the Annual Meeting, three (3) proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:

 

Proposal No. 1: The election of Christopher Missling, PhD, Claus van der Velden, PhD, Athanasios Skarpelos, Jiong Ma, PhD, Steffen Thomas, PhD and Peter Donhauser, D.O. for terms until the next succeeding annual meeting of stockholders or until such directors’ successor shall have been duly elected and qualified. The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy elected the six (6) directors by the following votes:

 

Name   For   Withheld   Broker Non-Votes
Christopher Missling, PhD     29,349,878       1,247,751       22,757,518  
Claus van der Velden, PhD     26,944,554       3,653,075       22,757,518  
Athanasios Skarpelos     27,597,270       3,000,359       22,757,518  
Jiong Ma, PhD     29,211,216       1,386,413       22,757,518  
Steffen Thomas, PhD     27,476,278       3,121,351       22,757,518  
Peter Donhauser, D.O.     27,155,102       3,442,527       22,757,518  

 

Proposal No. 2: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy ratified Grant Thornton LLP as the Company’s independent registered accounting firm by the following votes:

 

For   Against   Abstain   Broker Non-Votes
  52,369,399       452,908       532,840        

 

Proposal No. 3: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy voted to approve the 2022 Omnibus Incentive Plan by the following votes:

 

For   Against   Abstain   Broker Non-Votes
  19,233,911       10,676,227       687,491       22,757,518  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANAVEX LIFE SCIENCES CORP.
   
  /s/ Christopher Missling
  Name: Christopher Missling, PhD
  Title: Chief Executive Officer
   
Date: May 27, 2022  

 

 

 

Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Anavex Life Sciences Charts.